<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48054">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480621</url>
  </required_header>
  <id_info>
    <org_study_id>623477-4</org_study_id>
    <nct_id>NCT02480621</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine With Bupivacaine in Ankle Fracture ORIF</brief_title>
  <official_title>The Impact of Liposomal Bupivicaine on Post-Operative Pain in Orthopaedic Trauma Surgery: A Double-Blind Prospective Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jamaica Hospital Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jamaica Hospital Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized controlled trial assessing pain control in ankle fractures
      repaired with open reduction and internal fixation. Patients are consented and enrolled
      pre-operatively, and randomized to either control or liposomal bupivacaine with bupivacaine
      administered intra-operatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized controlled trial assessing pain control in ankle
      fractures repaired with open reduction and internal fixation. Patients are consented and
      enrolled pre-operatively, and randomized to either control or liposomal bupivacaine with
      bupivacaine administered intra-operatively. Patients are to remain blinded to the treatment
      arm. The surgeon is non-blinded and administers the bupivacaine solution locally,
      intra-operatively.

      Patients pain scores and pain medication usage is documented. A trained research coordinator
      contacts each patient at 24, 48, and 72 hours post-operatively to assess pain levels on a
      VAS scale and pain medications taken. Patients return for followup at standard intervals of
      2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively to assess healing and
      functional outcomes. Patients are queried as to satisfaction with pain control at 2 weeks
      post-operatively. The study will compare outcomes including pain levels, pain medications
      taken, OR and PACU times, LOS, satisfaction with pain control, clinical outcomes, and
      complication rates.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Levels on a Visual Analog scale ( VAS)</measure>
    <time_frame>Immediate post-operative period until 72 hours post-operatively</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ankle Fracture</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care: Open Reduction Internal Fixation with no injection of pain medications around the affected ankle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine with Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-operatively, patients receive a local injection of liposomal bupivacaine with bupivacaine around the affected ankle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine with Bupivacaine</intervention_name>
    <description>Pain medications injected locally during surgery around affected ankle.</description>
    <arm_group_label>Liposomal Bupivacaine with Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients at least 18 years old.

          2. Male or Female

          3. All racial and ethnic groups

          4. Fractures and fracture/dislocations of the ankle

          5. Patients who opt for surgical treatment of their fractures.

          6. Patients who consent to be randomized.

          7. Patients who are willing to follow-up for a minimum of 52 weeks.

        Exclusion Criteria:

          1. Patients younger than 18 years old

          2. Patients who are on chronic opioids

          3. Patients who abuse opioids

          4. Patients who are unwilling to follow-up for a minimum of 52 weeks

          5. Neurologic condition that could interfere with pain sensation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Davidovitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jamaica Hospital Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roy Davidovitch, MD</last_name>
    <phone>718-206-6923</phone>
    <email>roy.davidovitch@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jamaica Hospital Medical Center</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Robitsek, PhD</last_name>
      <phone>718-206-7173</phone>
      <email>jrobitse@jhmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Owen RT. Bupivacaine liposome injectable suspension: a new approach to postsurgical pain. Drugs Today (Barc). 2013 Aug;49(8):475-82. doi: 10.1358/dot.2013.49.8.2006992.</citation>
    <PMID>23977664</PMID>
  </reference>
  <reference>
    <citation>Joshi GP, Cushner FD, Barrington JW, Lombardi AV Jr, Long WJ, Springer BD, Stulberg BN. Techniques for periarticular infiltration with liposomal bupivacaine for the management of pain after hip and knee arthroplasty: a consensus recommendation. J Surg Orthop Adv. 2015 Spring;24(1):27-35.</citation>
    <PMID>25830260</PMID>
  </reference>
  <reference>
    <citation>Lonner JH, Scuderi GR, Lieberman JR. Potential utility of liposome bupivacaine in orthopedic surgery. Am J Orthop (Belle Mead NJ). 2015 Mar;44(3):111-7. Review.</citation>
    <PMID>25750943</PMID>
  </reference>
  <reference>
    <citation>Robbins J, Green CL, Parekh SG. Liposomal bupivacaine in forefoot surgery. Foot Ankle Int. 2015 May;36(5):503-7. doi: 10.1177/1071100714568664. Epub 2015 Jan 22.</citation>
    <PMID>25614060</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 23, 2016</lastchanged_date>
  <firstreceived_date>June 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jamaica Hospital Medical Center</investigator_affiliation>
    <investigator_full_name>Roy Davidovitch, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Ankle Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
